Further mechanistic investigations demonstrate that this vulnerability in cancer cells lacking ARID1D results from low basal levels of GSH due to reduced expression of SLC7A11 caused by impaired ARID1A-mediated chromatin remodeling and transcriptional activation. This evidence concerns the gene ARID1A and cancer.